US3577514A - Sustained release pharmaceutical tablets - Google Patents

Sustained release pharmaceutical tablets Download PDF

Info

Publication number
US3577514A
US3577514A US735571A US3577514DA US3577514A US 3577514 A US3577514 A US 3577514A US 735571 A US735571 A US 735571A US 3577514D A US3577514D A US 3577514DA US 3577514 A US3577514 A US 3577514A
Authority
US
United States
Prior art keywords
tablets
weight
drug
rate
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US735571A
Other languages
English (en)
Inventor
Ira C Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of US3577514A publication Critical patent/US3577514A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Definitions

  • a sustained release pharmaceutical tablet characterized by a substantially constant rate of drug release comprising: (a) a medicament; (b) a hydrophobic dissolution retardant; (c) an acid-insoluble release agent; and (b) a water-soluble or dispersible binder.
  • This invention relates to novel orally administrable dosage forms.
  • it relates to the preparation of sustained release tablets capable of disintegrating at a constant and uniform rate.
  • dosage forms enable the physician to more carefully regulate the level of drug administration to the patient.
  • a further advantage of sustained release dosage forms to the patient is the fact that a lesser number of them need be taken during the course of treatment.
  • one means for obtaining the above objective is to employ capsules or tablets which release the drug at a uniform rate during the capsules passage through the gastro-intestinal tract.
  • this object has been achieved by admixing one or more inert ingredients with the drug in such a manner that these inactive materials interfere with the disintegration of the tablet or the dissolution of the drug.
  • An obvious form of such a tablet is one wherein a core containing the active ingredient is surrounded by a layer of inert materials.
  • the tablet may be coated with an enteric substance, in which case the tablet passes unchanged through the stomach and disintegrates in the intestinal tract.
  • tablets can be composed of several alternate layers of medicament and inert material. In this manner, as each alternate protective layer disintegrates the patient receives a further dose of medicament.
  • tablets of this type suffer from the disadvantage of not providing a uniform and constant drug release. Furthermore, such tablets are difficult to prepare with precision so that in many instances the desired dosage level cannot be assured.
  • the present invention describes sustained release dosage forms which will provide a uniform and constant liberation of medicament
  • This invention comprises a sustained release pharmaceutical tablet comprising: (a) a medicament; (b) a hydrophobic dissolution retardant; (c) an acid insoluble release agent; and (d) a water soluble or dispersible binder.
  • the product of this invention is characterized by having a substantially constant erosion rate in gastro-in- 3,577,514 Patented May 4, 1971 testinal fluid wherein the medicament is released at a constant and uniform rate.
  • This invention further comprises a sustained release pharmaceutical tablet containing up to 70% by weight of a medicament, 15-50% by Weight of a hydrophobic dissolution retardant, 0.l5.0% by weight of an acid-insoluble release agent and 5-15 by weight of a water soluble or dispersible binder.
  • the formulation comprises an intimate uniform blend of a water soluble or insoluble medicament, a hydrophobic dissolution retardant, an acid-insoluble release agent, and a water soluble or dispersible binder.
  • Other customary tablet ingredients such as fillers, colorants, lubricants, stabilizers and excipients can also be included in the formulation as required. Tabletting of this blend provides a pharmaceutical tablet wherein the aforesaid constituents are uniformly dispersed throughout the tablet matrix.
  • the blend can be formulated into a capsular form as well.
  • the range of the basic ingredients can be varied over a considerable latitude and yet will provide an orally administrable dosage form having a constant and uniform rate of disintegration, Thus, the following ranges have been found to be effective (the percentages are by weight): up to 70% of medicament; 15-50% of hydrophobic dissolution retardant; 0.l5% of acid insoluble release agent; and 5-15 of a water soluble binder.
  • a preferred formulation would comprise about 5-25% of medicament; 2030% of hydrophobic dissolution retardant; 05-10% of acid-insoluble release agent; and -11% of water-soluble binder.
  • An outstanding advantage of the present invention is the fact that a mixture of Water soluble and insoluble medicaments can be incorporated into the blend and after tableting each individual medicament will he released from the tablet at a uniform and constant rate.
  • a sustained release dosage form containing theophylline, ephedrine sulfate and hydroxyzine hydrochloride, wherein each pharmaceutical has been found to be released in simulated intestinal fluid at a reasonably constant and uniform rate.
  • medicaments can be used in the instant invention, such as antihistamines, hypoglycemics, antidepressants, coronary vasodilators, bronchodilators, sedatives, decongestants, antispasmodics, vitamins, and the antibiotics.
  • hydrophobic dissolution retardants by virtue of their water insolubility, function by retarding the dissolution and diffusion of the drug from the tablet or granulates into the gastro-intestinal fluid
  • hydrophobic dissolution retardants that we have found effective are the natural and synthetic waxes, resins and plastics. Of these we prefer carnauba wax, beeswax, spermaceti, and the commercial product Sterotex K-lOO, which is a hydrogenated cottonseed oil available from Capital City Products, Columbus, Ohio.
  • Enteric substances insoluble in the acidic stomach juices, are the preferred acid-insoluble release agents.
  • cellulose acetate phthalate and the other acetate phthalates are preferable.
  • the esters of the carbohydrate polymers are preferable.
  • the phthalic acid derivatives of polyacrylic acid are preferable.
  • the effect of the water-soluble or dispersible binder is to insure a uniform release of the drug.
  • the binders of choice are the polyvinyl pyrrolidones, acacia and other water-soluble or dispersible binders well known to those skilled in the art, may be used.
  • antioxidants e.g., ascorbic acid, sodium metabisulfite
  • lubricants e.g., talc, magnesium stearate and sodium lauryl sulfate
  • fillers e.g., calcium diphosphate
  • colorants are generally added to further improve the product.
  • the tablets can be prepared from the blended ingredients in the usual manner, e.g., dry blending followed by compression into tablets, or dry slugging and granulating the blended ingredients prior to compressing them into tablets, etc.
  • the tablets may also be prepared by first wet granulating the blend with a suitable solvent or binder solution or dispersion, such as alcohol or polyvinyl pyrrolidone colloidal solution.
  • the tablet erosion studies are conducted with the tablet distintegration apparatus described in U.S.P. XVII. Simulated gastro-intestina] fluids, the preparation of which are described in U.S.P. XVII, are used in the test.
  • the tablets are placed in the apparatus and initially contacted with simulated gastric juices for one hour. The weight loss of the tablets is then determined. The gastric juice is then removed, simulated intestinal fluid is added to the apparatus, and the course of the disintegration of the tablets is followed over the course of the next few hours by periodically determining the weight loss of the tablets.
  • the drug dissolution rate is also determined in this test by periodically assaying the amount of drug that dissolves in these fluids over the course of several hours. The drug dissolution rate ran also be determined by the in vitro test for timed-release capsules and tablets outlined in the second supplement of N. F. XII.
  • EXAMPLE I The ingredients listed below are dry blended and directly compressed into tablets on a rotary or single punch tableting machine:
  • Time/hours percent percent I First hour in gastric juice; thereafter in intestinal fluid.
  • the particles are passed through a 40 mesh screen using a Fitzmill, hammers leading at medium speed.
  • the mixture is reblended for 30 minutes and moistened with 50 g. of methanol in a Hobart blender.
  • the moist mixture is passed through a 40 mesh screen (Fitzmill, hammers leading at medium speed).
  • the final mixture is air dried without heat for 3045 minutes.
  • the magnesium stearate is then added and the mixture is blended for 5 to 10 minutes.
  • the tablets are prepared by compressing on a rotary tablet press using in. standard round concave punches and dies, to a thickness of 014110.005 in. thick and a hardness of 7 kg. (Pfizer tester).
  • the rate of drug dissolution is determined in the same manner as detailed above.
  • EXAMPLE III With the exception of magnesium stearate, the ingredients listed below are dry-blended for 15 minutes and passed through a 40 mesh screen:
  • the ingredients are reblended for 30 minutes and moistened with 75 g. of 2B ethanol.
  • the mixture is stirred in a Hobart mixer until nearly dry and passed through a 40 mesh screen and reblended.
  • the mixture is then air dried until the odor of the solvent is no longer detectable, and the lubricant is added.
  • the mixture is briefly blended and compressed into tablets under the following conditions: the dry powder granulates are placed in the hopper without further processing and compacted into tablets using in. standard round concave punches and dies on a rotary tablet press to a hardness of 7 kg. (Pfizer tester).
  • EXAMPLE V With the exception of magnesium stearate, the ingredients listed below are blended together for 30 minutes in a suitable blender, after passage through a 40 mesh screen 5 on a Fitzmill comminator. A portion of the magnesium th The "E qif g fi lgdetmumd ldenucany to stearate (1.5%) is added, and the mixture is briefly blende Prevlous Y 6 met 0 ed and slugged with /2 in. standard round flat punches D RUG DISSOLUTION RATES and dies to a hardness of 8 kg. and 400 mg. weight.
  • the Amount slugs are granulated through an 18 mesh screen on an Cumulattive Amr mnt oi (lumulat ive g1 bma 10 oscillating granulator.
  • the remainder of the magnesium 3,1 3,233.3 i fig gggg g fg g, stearate is blended into the resultant granulation.
  • the Ti r a d. h u r e blend is compressed on a suitable tablet press, to a weight perm percent pmen perm of 512.5 mg. for a hardness of 10 kg. (Pfizer tester).
  • Theophylline 400 200 (39 J 5 5 4 m Ephedrine sulfate 100 50 9. @9 3 I First hour in gastric juice; thereafter in intestinal fluid. giggg y g gi ggggggg fi f ffi g 87%) Oab'O-SiI III 10 5 EXAMPLE IV Sterotex K-IOO 260 130 (25.
  • Fines 60 mesh are separated and 0 53: Pfiggent thoroughly blended with the metamlne. This mixture con- 3 Time/hours 1035 g; taining the active drug is blended with the remainder, the 229 22 9 dry granulation. The remaining half of magnesium stearate is added to the total blend of granules, followed by 1 15.8 13.1 brief reblending. Tablets are prepared by compressing on 15:9 arrgcsgrgzblet press in accordance with previously defined mm hour in gastric juice; thereafter In intestinal fluid.
  • EXAMPLE VI I First hour in gastric juice; thereafter in intestinal fiuid. The rate of drug dissolution is as follows:
  • the rate of disintegration and rate of drug dissolution of these tablets are found to be constant and uniform when determined according to the tests described in the preceding examples.
  • the rate of disintegration and rate of drug dissolution of these tablets are found to be constant and uniform when determined according to the tests described in the preceding examples.
  • Tests A, B, and C below are conducted with the disintegration apparatus described in USP XVII.
  • Tests A and B the tablets are contacted with gastric juice to 1 hour and then with intestinal fluid to 4 hours. At the end of the 4 hour period the tablets are contacted with fresh intestinal fluid to 7 hours.
  • Test C the tablets are contacted with gastric juice for the first hour and thereafter 'with intestinal fluid, with hourly change to fresh fluid.
  • Test C.l44 tablets Amount of metamine Time/hours: released/ time interval 1 30.4
  • Test D This test is conducted according to the procedure in N.F. XII, using 12 tablets per screw cap bottle.
  • Metamine dissolution rate Metamlne dissolution rate l A sustained released pharmaceutical tablet essentially containing, uniformly dispersed throughout the tablet matrix, about 5 up to 70% by weight of a medicament, 550% by weight of a hydrophobic dissolution retardant selected from the group consisting of hydrogenated cottonseed oil, hydrogenated castor oil, carnauba wax, beeswax, spermaceti, and shellac, ill-5.0% by Weight of an enteric acid-insoluble release agent selected from the group consisting of cellulose acetate phthalate, starch acetate phthalate and a phthalic acid derivative of polyacrylic acid, and 5-15% by weight of a water-soluble or dispersible binder, eifective to insure a uniform release of the medicament, selected from the group consisting of polyvinyl pyrrolidone and acacia.
  • a hydrophobic dissolution retardant selected from the group consisting of hydrogenated cottonseed oil, hydrogenated castor oil, carnauba
  • a sustained release pharmaceutical tablet according to claim 1 comprising: (a) 56% by weight of triethanolamine trinitrate biphosphate; (b) 22-25% by weight of carnauba wax; (c) 0.80-1.20% by weight of cellulose acetate phthalate; and (d) 812% by weight of polyvinyl pyrrolidone.
  • a sustained release pharmaceutical tablet according to claim 1 comprising: (a) 57% by weight of triethan0l amine trinitrate biphosphate; (b) 2225% by weight of butabarbital; (c) 13-17% by weight of hydrogenated cottonseed oil; (cl) 24% by weight of cellulose acetate phthalate; and (e) 13-18% by weight of polyvinylpyrrolidone.
  • a sustained release pharmaceutical tablet comprising: (a) 37-41% by weight of theophylline; (b) 8-1l% by weight of ephedrine sulfate; (c) 4-6% by weight of hydroxyzine dihydrochloride; (d) 23- 10 26% by weight of cottonseed oil; (e) (LS-1.2% by weight of cellulose acetate phthalate; and (f) 812% by weight of polyvinylpyrrolidone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
US735571A 1968-06-10 1968-06-10 Sustained release pharmaceutical tablets Expired - Lifetime US3577514A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73557168A 1968-06-10 1968-06-10

Publications (1)

Publication Number Publication Date
US3577514A true US3577514A (en) 1971-05-04

Family

ID=24956332

Family Applications (1)

Application Number Title Priority Date Filing Date
US735571A Expired - Lifetime US3577514A (en) 1968-06-10 1968-06-10 Sustained release pharmaceutical tablets

Country Status (4)

Country Link
US (1) US3577514A (enrdf_load_stackoverflow)
DE (1) DE1927130A1 (enrdf_load_stackoverflow)
FR (1) FR2010541A1 (enrdf_load_stackoverflow)
GB (1) GB1235787A (enrdf_load_stackoverflow)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3909444A (en) * 1971-08-05 1975-09-30 Ncr Co Microcapsule
US4189469A (en) * 1975-05-10 1980-02-19 Hoechst Aktiengesellschaft Pharmaceutical compositions
US4244941A (en) * 1972-10-06 1981-01-13 Gist-Brocades N.V. Controlled release composition and process for preparing same
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
DE3100191A1 (de) * 1980-01-11 1981-12-10 The Boots Co. Ltd., Nottingham Pharmazeutische zubereitung und verfahren zu ihrer herstellung
US4308251A (en) * 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
WO1984004674A1 (en) * 1983-05-31 1984-12-06 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
EP0103387A3 (en) * 1982-08-12 1984-12-12 Pfizer Inc. Long-acting matrix tablet formulations
US4521401A (en) * 1983-01-03 1985-06-04 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of quinidine
US4522804A (en) * 1983-01-03 1985-06-11 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of propranolol
US4540602A (en) * 1979-04-13 1985-09-10 Freund Industry Company, Limited Process for the preparation of activated pharmaceutical compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US4608248A (en) * 1985-11-08 1986-08-26 Warner-Lambert Company Process for time-controlled release of active ingredients
US4726952A (en) * 1983-08-11 1988-02-23 Mission Pharmacal Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
US4882167A (en) * 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4904478A (en) * 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
US4960814A (en) * 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US5025004A (en) * 1988-06-13 1991-06-18 Eastman Kodak Company Water-dispersible polymeric compositions
US20060147526A1 (en) * 2002-11-29 2006-07-06 Cipla Limted Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines
US20070042041A1 (en) * 2005-08-17 2007-02-22 Board Of Trustees Of The University Of Arkansas Drug-surfactant complexes for sustained release
US20070207203A1 (en) * 2006-03-02 2007-09-06 Xiu Xiu Cheng And Dacheng Tian Oral controlled release formulation for sedative and hypotnic agents
US11160758B2 (en) 2019-06-04 2021-11-02 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US11370753B2 (en) 2017-12-05 2022-06-28 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US11517558B2 (en) 2017-12-05 2022-12-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE773113A (fr) * 1970-09-28 1972-01-17 Controlled Medications Composition pharmaceutique a liberation progressive de la substance active
FR2183546B1 (enrdf_load_stackoverflow) * 1972-05-10 1975-06-20 Servier Lab
DE3524003A1 (de) 1985-07-04 1987-01-08 Heumann Ludwig & Co Gmbh Arzneimittelgranulat mit verzoegerter wirkstofffreisetzung und verfahren zu seiner herstellung

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3909444A (en) * 1971-08-05 1975-09-30 Ncr Co Microcapsule
US4244941A (en) * 1972-10-06 1981-01-13 Gist-Brocades N.V. Controlled release composition and process for preparing same
US4189469A (en) * 1975-05-10 1980-02-19 Hoechst Aktiengesellschaft Pharmaceutical compositions
US4540602A (en) * 1979-04-13 1985-09-10 Freund Industry Company, Limited Process for the preparation of activated pharmaceutical compositions
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
DE3100191A1 (de) * 1980-01-11 1981-12-10 The Boots Co. Ltd., Nottingham Pharmazeutische zubereitung und verfahren zu ihrer herstellung
US4308251A (en) * 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
EP0103387A3 (en) * 1982-08-12 1984-12-12 Pfizer Inc. Long-acting matrix tablet formulations
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4521401A (en) * 1983-01-03 1985-06-04 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of quinidine
US4522804A (en) * 1983-01-03 1985-06-11 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of propranolol
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
WO1984004674A1 (en) * 1983-05-31 1984-12-06 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4882167A (en) * 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4904478A (en) * 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
US4726952A (en) * 1983-08-11 1988-02-23 Mission Pharmacal Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US4608248A (en) * 1985-11-08 1986-08-26 Warner-Lambert Company Process for time-controlled release of active ingredients
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4960814A (en) * 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US5025004A (en) * 1988-06-13 1991-06-18 Eastman Kodak Company Water-dispersible polymeric compositions
US20060147526A1 (en) * 2002-11-29 2006-07-06 Cipla Limted Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines
US20100105637A1 (en) * 2005-08-17 2010-04-29 Kim Cherng-Ju Drug-surfactant complexes for sustained release
US20070042041A1 (en) * 2005-08-17 2007-02-22 Board Of Trustees Of The University Of Arkansas Drug-surfactant complexes for sustained release
US20070207203A1 (en) * 2006-03-02 2007-09-06 Xiu Xiu Cheng And Dacheng Tian Oral controlled release formulation for sedative and hypotnic agents
US20090123535A1 (en) * 2006-03-02 2009-05-14 Xiu Xiu Cheng Oral Controlled Release Formulation for Sedatives and Hypnotic Agents
US8309104B2 (en) * 2006-03-02 2012-11-13 Watson Pharmaceuticals, Inc. Oral controlled release formulation for sedative and hypnotic agents
US11370753B2 (en) 2017-12-05 2022-06-28 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US11517558B2 (en) 2017-12-05 2022-12-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US11767293B2 (en) 2017-12-05 2023-09-26 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US12161623B2 (en) 2017-12-05 2024-12-10 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US11160758B2 (en) 2019-06-04 2021-11-02 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US11654113B2 (en) 2019-06-04 2023-05-23 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US12161758B2 (en) 2019-06-04 2024-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Also Published As

Publication number Publication date
FR2010541A1 (enrdf_load_stackoverflow) 1970-02-20
DE1927130A1 (de) 1969-12-11
GB1235787A (en) 1971-06-16

Similar Documents

Publication Publication Date Title
US3577514A (en) Sustained release pharmaceutical tablets
US3965256A (en) Slow release pharmaceutical compositions
US4235870A (en) Slow release pharmaceutical compositions
US2887438A (en) Prolonged action tablets
CA1199870A (en) Prolonged-action multiple-layer tablets
US3728445A (en) Controlled release medicament
EP0345787B1 (en) Drug in combination with flavor masking agent and method for making same
AT394310B (de) Verfahren zur herstellung lagerstabiler, schnellzerfallender pharmazeutischer wirkstoff-presslinge
US4650664A (en) Oral mopidamol preparation
EP0173210B1 (de) Pellet-Zubereitung
US3427378A (en) Sustained release encapsulated formula
US3362881A (en) Sustained release tablet and method of manufacturing same
EP0108218A2 (en) Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility
FI101040B (fi) Menetelmä sentraalisten dopamiininpuutostilojen hoitoon tarkoitetun, p eroraalisesti annettavan lääkemuodon valmistamiseksi
JPH07509479A (ja) 長期間にわたって２段階で放出する形態を有する固体の薬剤投与形態およびその製造
US6620432B2 (en) Phenytoin sodium pharmaceutical compositions
GB2101484A (en) Oral dipyridamole compositions
JPH02138210A (ja) 圧縮成型製剤
US3078216A (en) Prolonged release oral pharmaceutical preparations
JPH0228564B2 (enrdf_load_stackoverflow)
JP2024180618A (ja) レベチラセタムを含む錠剤
US3102845A (en) Pharmaceutical tablet
US4444769A (en) Antihypertensive diuretic combination composition and associated method
GB2123291A (en) Suloctidil compositions
US3039922A (en) Method of administering tablets having decongestant and anti-histaminic activity